bioRxiv Science⌕ Search

Biology subjects

Serrano-Regal, M. P.

Publications and source records attributed to Serrano-Regal, M. P..

2 recordsLinked to original sources

Circulating Myeloid-Derived Suppressor Cell load and disease severity are associated to an enhanced oligodendroglial production in a murine model of multiple sclerosis

BackgroundMultiple sclerosis (MS) is a chronic, inflammatory and demyelinating disease of the central nervous system (CNS) that is highly heterogeneous in terms of disease severity and tissue damage extent. Improving myelin restoration is essential to prevent neurodegeneration and the associated disability in MS patients. However, remyelinating therapies are failing in clinical trials, in part, due to the absence of classifying biomarkers of different endogenous regenerative capacities amongst enrolled patients. We previously reported that circulating monocytic myeloid-derived suppressor cells (M-MDSCs) at the onset of the murine model of MS experimental autoimmune encephalomyelitis (EAE) are associated with milder disease courses and less degree of demyelination and axonal damage in spinal cord lesions, while at peak are indicative of a better symptom recovery. Moreover, M-MDSCs are able to promote in vitro oligodendrocyte precursor cell (OPC) proliferation and differentiation towards mature oligodendrocytes (OLs) through the release of the soluble factor osteopontin. ResultsHere, we show a relationship between disease severity and a gradient of OPCs between the rim and the core in mixed active-inactive lesions of MS patients, along with a positive correlation between M-MDSC density and OPC abundance in the same lesions. We also show that EAE disease severity negatively influences the density of total and newly generated OPCs found associated to the demyelinated lesions of the spinal cord at the peak of the disease. In addition, disease severity also impacts the abundance of newly generated OLs originated either during the effector phase or during the early recovery phase. We also demonstrate the positive association between infiltrated M-MDSCs and the abundance of OPCs in the periplaque of demyelinating lesions at the peak of EAE. Interestingly, circulating M-MDSCs at EAE onset and peak of the disease are directly associated to a higher density of newly generated OLs in the plaque and periplaque, respectively. ConclusionDisease severity clearly impacts oligodendrocyte generation during a neuroinflammatory insult like EAE. Our results set the basis for further studies on M-MDSCs as a promising new biomarker that identify a CNS prone to the generation of new OLs that may contribute to restore myelin.

neuroscience↗

GABABR agonist baclofen promotes central nervous system remyelination

Promoting remyelination - the endogenous response by which lost myelin sheaths are regenerated - is considered as a potential neuroprotective strategy to prevent/limit the development of permanent neurological disability in patients with multiple sclerosis (MS). To this end, a number of clinical trials are investigating the potential of existing drugs to enhance oligodendrocyte progenitor cell (OPC) differentiation, the process that fails in chronic MS lesions. As we previously reported that oligodendroglia lineage cells express GABAB receptors (GABABRs) both in vitro and in vivo, and that GABABR-mediated signaling enhances OPC differentiation and myelination in vitro, here we focused on the remyelinating potential of the best-known GABABR agonist baclofen (Bac), already approved to treat spasticity in MS. We demonstrated that Bac increases myelin protein production following lysolecithin (LPC)-induced demyelination in cerebellar ex vivo slices. In addition, Bac administration enhanced OPC differentiation and remyelination in LPC-induced spinal cord lesions in adult mice. Thus, our results suggest that Bac should be considered as a potential therapeutic agent, not only to treat spasticity, but also to improve remyelination in patients with MS.

neuroscience↗